With last month’s celebration of Rare Disease Month and specifically, Rare Disease Day, awareness of the research challenges faced by patients and pharma companies are especially high during this season.
March 21, 2018
Why would anyone go through the trouble of getting the supplies and putting in the effort to attempt a job well done if they couldn’t see their progress along the way? Just the same, why would anyone turn their career over to the annual performance review process?
January 10, 2018
CYCLE FOR SURVIVAL 2018Every dollar represents hope, strength, and a lasting impact! |
October 3, 2017
In pharmaceutical clinical trials, considering competing risk analyses is highly important. Competing risks are events that may occur and prevent the evaluation of a specific primary endpoint, in turn biasing risk estimations or drug efficacy.
August 15, 2017
Veristat has completed the validation and configuration of Master Control’s eTMF system, which is now implemented and available for Veristat managed clinical trials.
August 3, 2017
Last week, Veristat attended the Massachusetts Biotechnology Council (MassBio) forum titled “Evolution of an Academic Discovery: First Person Account of the Development of Velcade®”.
February 23, 2017
On Saturday, February 4, Team Veristat joined the battle against rare cancers at the 2017 Cycle for Survival event! Team Veristat had 14 riders at the Boston, MA event, including 2 colleagues from our UK office. Our team surpassed our goal of raising over $25,000 to fund rare cancer research!
January 5, 2017
For anyone who follows this blog with even moderate consistency, it is probably clear that Veristat is a growing organization. It is hopefully just as apparent that we are a group who tremendously values and fiercely protects our culture.
December 15, 2016
Read more about this and the discussions that you missed at the MassBio Forum on Adaptive Designs in Clinical Research that took place last month.
